UNSPSC 51422350: Halometasone monohydrate

This classification denotes a betamethasone analog C22H27ClF2O5.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0PJ4SNG9CS, chemically known as pregna-1,4-diene-3,20-dione, 2-chloro-6,9-difluoro-11,17,21-trihydroxy-16-methyl-, hydrate (1:1), (6.alpha.,11.beta.,16.alpha.)-, but more generally known as halometasone monohydrate, which bears US NIH Compound Identifier 9846332. Most nations, for tariff and trade purposes, schedule halometasone monohydrate under HS 29372200 and SITC 54153.

As of Q4 2014, HALOMETASONE MONOHYDRATE remains US FDA's Preferred Term for this commodity. SMILES: C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C(=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C)CL)F.O.

UNSPSC 51422350 Halometasone monohydrate is a Commodity code whose recent state and local activity shows a substantial mismatch between the nominal pharmaceutical ingredient and the work actually being solicited. The recent opportunities tagged to this code involve naloxone procurement and direct-to-manufacturer pharmacy benefit programs — neither of which involves halometasone monohydrate specifically. State and local issuers appear to be using this code as a catch-all pharmaceutical or health-services classification rather than purchasing the specific corticosteroid named in the code. The scope of work reflected in recent solicitations spans opioid overdose reversal supplies (naloxone kits) and pharmacy supply-chain restructuring to bypass traditional pharmacy benefit managers and group purchasing organizations in favor of direct manufacturer relationships.

Recent activity includes Seminole County, Florida issuing IFB 60459723LAS on June 30, 2026, for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with a July 26, 2023 response deadline, requiring quarterly deliveries to the Seminole County Community Health Building and compliance with drug-free workplace and E-Verify requirements. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program designed to establish direct state-agency contracting with pharmaceutical manufacturers outside traditional pharmacy benefit manager arrangements. Both solicitations target state and county health agencies; geographic activity is concentrated in Florida and Texas. Because the recent opportunities show no purchases of halometasone monohydrate itself, the code's real market value for vendors lies in understanding how state and local health procurement is evolving toward overdose-reversal supplies and alternative pharmacy contracting models rather than the corticosteroid classification the code nominally describes.